248 related articles for article (PubMed ID: 30341683)
1. Doravirine: First Global Approval.
Deeks ED
Drugs; 2018 Oct; 78(15):1643-1650. PubMed ID: 30341683
[TBL] [Abstract][Full Text] [Related]
2. Doravirine: a new non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Talwani R; Temesgen Z
Drugs Today (Barc); 2020 Feb; 56(2):113-124. PubMed ID: 32163527
[TBL] [Abstract][Full Text] [Related]
3. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
[TBL] [Abstract][Full Text] [Related]
4. Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Yee KL; DiBenedetto A; Fan L; Khalilieh S; Triantafyllou I; Vallee MH; Fackler P; Stoch SA; Iwamoto M
AAPS PharmSciTech; 2020 Feb; 21(3):91. PubMed ID: 32060665
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; Klopfer SO; Grandhi A; Eves K; Hepler D; Robertson MN; Hwang C; Hanna GJ; Correll T
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):68-72. PubMed ID: 35972855
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Vaddady P; Kandala B; Yee KL
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868326
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Kumar P; Johnson M; Molina JM; Rizzardini G; Cahn P; Bickel M; Wan H; Xu ZJ; Morais C; Sklar P; Greaves W;
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):801-805. PubMed ID: 33633036
[TBL] [Abstract][Full Text] [Related]
8. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
Boyle A; Moss CE; Marzolini C; Khoo S
Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Wong A; Goldstein D; Mallolas J; DeJesus E; Johnson M; Molina JM; Pozniak A; Rodgers A; Teal V; Hepler D; Kumar S; Sklar P; Hanna GJ; Hwang C; Badshah C; Teppler H
J Acquir Immune Defic Syndr; 2019 Dec; 82(4):e47-e49. PubMed ID: 31425317
[TBL] [Abstract][Full Text] [Related]
10. Rational Design of Doravirine: From Bench to Patients.
Hwang C; Lai MT; Hazuda D
ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
[TBL] [Abstract][Full Text] [Related]
11. The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
Huang XS; Luo RH; Hu XL; Chen H; Xiang SY; Tang CR; Zhang CT; Shen XN; Zheng YT
Curr HIV Res; 2020; 18(5):332-341. PubMed ID: 32562524
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1.
Yee KL; Ouerdani A; Claussen A; de Greef R; Wenning L
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745394
[TBL] [Abstract][Full Text] [Related]
14. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Rodgers A; Lupinacci L; Kumar S; Sklar P; Hanna GJ; Hwang C; Martin EA;
Lancet HIV; 2020 Jan; 7(1):e16-e26. PubMed ID: 31740348
[TBL] [Abstract][Full Text] [Related]
15. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Asante-Appiah E; Lai J; Wan H; Yang D; Martin EA; Sklar P; Hazuda D; Petropoulos CJ; Walworth C; Grobler JA
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0121621. PubMed ID: 34570651
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Melvin AJ; Yee KL; Gray KP; Yedla M; Wan H; Tobin NH; Teppler H; Campbell H; McCarthy K; Scheckter R; Aurpibul L; Ounchanum P; Rungmaitree S; Cassim H; McFarland E; Flynn P; Cooper E; Krotje C; Townley E; Moye J; Best BM;
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):153-161. PubMed ID: 36215957
[TBL] [Abstract][Full Text] [Related]
17. Bictegravir: First Global Approval.
Markham A
Drugs; 2018 Apr; 78(5):601-606. PubMed ID: 29564777
[TBL] [Abstract][Full Text] [Related]
18. Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
Lai MT; Feng M; Xu M; Ngo W; Diamond TL; Hwang C; Grobler JA; Hazuda DJ; Asante-Appiah E
Antimicrob Agents Chemother; 2022 May; 66(5):e0222321. PubMed ID: 35491829
[TBL] [Abstract][Full Text] [Related]
19. Doravirine: A Return of the NNRTI Class?
Blevins SR; Hester EK; Chastain DB; Cluck DB
Ann Pharmacother; 2020 Jan; 54(1):64-74. PubMed ID: 31416335
[No Abstract] [Full Text] [Related]
20. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
